Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in chronic rhinosinusitis with nasal polyps
NCT05274750Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of depemokimab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by GSK. Started Apr 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05274750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274750.